Bora Pharmaceuticals
Taiwan 712 employees Updated 9 July 2026
Bora Pharmaceuticals is a finished-dose manufacturer based in Taiwan. It appears in 13 regulatory filings across 2 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO) and NPRA (MY). Its most recent recorded inspection, by US FDA, closed on 30 August 2022 as VAI.
1
registered plants
1 with an FDA FEI number
13
filings
across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 30 August 2022 VAI US FDA
- 19 December 2018 VAI US FDA
- 21 June 2018 NAI US FDA
- 10 December 2015 NAI US FDA
- 3 March 2014 VAI US FDA
- 1 March 2013 VAI US FDA
- 28 February 2011 NAI US FDA
- 22 February 2011 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Maple Grove, United States | 3004106442 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| DIGEMAPS (DO) | 12 | None |
| NPRA (MY) | 1 | None |
Comparing suppliers?
Choose your molecules and target markets. Bora Pharmaceuticals comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 30 August 2022.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability